Ublituximab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ublituximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD20
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NYesY (what is this?)  (verify)

Ublituximab is an immunomodulator. It binds to CD20.[1]

It is currently in phase 2 trials for multiple sclerosis.[2]

References[edit]

  1. ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4). 
  2. ^ https://clinicaltrials.gov/ct2/show/NCT02738775